Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Bolt Biotherapeutics (BOLT) Net Margin (2020 - 2025)

Bolt Biotherapeutics (BOLT) has disclosed Net Margin for 6 consecutive years, with 268.72% as the latest value for Q4 2025.

  • Quarterly Net Margin changed N/A to 268.72% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 436.87% through Dec 2025, up 44471.0% year-over-year, with the annual reading at 436.87% for FY2025, 44471.0% up from the prior year.
  • Net Margin hit 268.72% in Q4 2025 for Bolt Biotherapeutics, up from 333.15% in the prior quarter.
  • In the past five years, Net Margin ranged from a high of 268.72% in Q4 2025 to a low of 5345.87% in Q4 2021.
  • Historically, Net Margin has averaged 1435.55% across 5 years, with a median of 1030.26% in 2022.
  • Biggest five-year swings in Net Margin: soared 392864bps in 2022 and later plummeted -68698bps in 2024.
  • Year by year, Net Margin stood at 5345.87% in 2021, then soared by 73bps to 1417.22% in 2022, then soared by 40bps to 857.01% in 2023, then tumbled by -55bps to 1330.06% in 2024, then surged by 80bps to 268.72% in 2025.
  • Business Quant data shows Net Margin for BOLT at 268.72% in Q4 2025, 333.15% in Q3 2025, and 477.33% in Q2 2025.